Windsor Capital Management LLC reduced its position in Johnson & Johnson (NYSE:JNJ) by 21.1% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 8,768 shares of the company’s stock after selling 2,346 shares during the period. Windsor Capital Management LLC’s holdings in Johnson & Johnson were worth $1,123,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Traynor Capital Management Inc. increased its stake in shares of Johnson & Johnson by 15.9% in the 1st quarter. Traynor Capital Management Inc. now owns 14,930 shares of the company’s stock valued at $1,913,000 after buying an additional 2,053 shares during the period. Mizuho Securities USA LLC grew its stake in shares of Johnson & Johnson by 602.0% during the first quarter. Mizuho Securities USA LLC now owns 129,905 shares of the company’s stock worth $16,647,000 after purchasing an additional 111,399 shares during the period. Ramsay Stattman Vela & Price Inc. grew its stake in shares of Johnson & Johnson by 1.5% during the first quarter. Ramsay Stattman Vela & Price Inc. now owns 68,894 shares of the company’s stock worth $8,829,000 after purchasing an additional 1,035 shares during the period. Court Place Advisors LLC grew its stake in shares of Johnson & Johnson by 11.5% during the first quarter. Court Place Advisors LLC now owns 14,558 shares of the company’s stock worth $1,866,000 after purchasing an additional 1,505 shares during the period. Finally, FormulaFolio Investments LLC grew its stake in shares of Johnson & Johnson by 11.5% during the first quarter. FormulaFolio Investments LLC now owns 5,825 shares of the company’s stock worth $746,000 after purchasing an additional 603 shares during the period. 65.97% of the stock is owned by institutional investors.
A number of brokerages recently commented on JNJ. Citigroup decreased their price objective on Johnson & Johnson from $150.00 to $146.00 and set a “neutral” rating for the company in a research note on Tuesday, February 27th. Zacks Investment Research cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Monday, April 16th. Credit Suisse Group set a $154.00 price objective on Johnson & Johnson and gave the stock a “buy” rating in a research note on Tuesday, April 17th. Deutsche Bank reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Wednesday, April 18th. Finally, Stifel Nicolaus decreased their price objective on Johnson & Johnson from $145.00 to $135.00 and set a “hold” rating for the company in a research note on Wednesday, April 18th. Six equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $142.23.
Shares of Johnson & Johnson opened at $122.35 on Wednesday, MarketBeat Ratings reports. The stock has a market capitalization of $328.90 billion, a PE ratio of 16.76, a PEG ratio of 1.88 and a beta of 0.73. Johnson & Johnson has a one year low of $118.62 and a one year high of $148.32. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.25 and a current ratio of 1.58.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 17th. The company reported $2.06 EPS for the quarter, beating analysts’ consensus estimates of $2.00 by $0.06. The company had revenue of $20.01 billion for the quarter, compared to analyst estimates of $19.50 billion. Johnson & Johnson had a return on equity of 30.65% and a net margin of 1.58%. The company’s quarterly revenue was up 12.6% compared to the same quarter last year. During the same period in the previous year, the company posted $1.83 earnings per share. analysts predict that Johnson & Johnson will post 8.13 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Tuesday, June 12th. Stockholders of record on Tuesday, May 29th were issued a $0.90 dividend. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.94%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.84. The ex-dividend date was Friday, May 25th. Johnson & Johnson’s payout ratio is 49.32%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.